GB-3007

N/A

Report date: 2022/10/18 14:46:07

Base Information

Drug NameGB-3007
Drug Alias NameGB 3007GB-3007
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsAnti-NY-ESO-1
TargetsCancer/testis antigen 1
Therapy Area/IndicationsSarcoma, Synovial
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesShanghai Genbase Biotechnology Co LtdShanghai Genechem Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Genbase Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsSarcoma, Synovial
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A